青海春天(600381) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥59,651,977.16, representing an increase of 11.94% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was -¥30,581,829.82, with a year-to-date net profit of -¥90,451,751.65[2]. - Total operating revenue for the first three quarters of 2024 reached ¥198,034,675.41, an increase of 23.1% compared to ¥160,712,654.06 in the same period of 2023[16]. - Net loss for the first three quarters of 2024 was ¥88,648,013.81, compared to a net loss of ¥68,576,421.15 in the same period of 2023, indicating a deterioration in financial performance[18]. - The basic and diluted earnings per share for Q3 2024 were both -¥0.053[3]. - The basic and diluted earnings per share for the first three quarters of 2024 were both -¥0.155, compared to -¥0.120 in the same period of 2023[19]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥19,456,771.80, showing a significant increase of 117.09%[3]. - Cash flow from operating activities was ¥188,407,604.97 for the first three quarters of 2024, compared to ¥174,195,469.42 in 2023, showing an increase of 8.2%[20]. - Operating cash inflow totaled CNY 193,069,418.50, an increase from CNY 179,140,626.75 in the previous period[21]. - Operating cash outflow amounted to CNY 173,612,646.70, compared to CNY 170,177,883.30 last year[21]. - Net cash flow from operating activities was CNY 19,456,771.80, up from CNY 8,962,743.45[21]. - The net increase in cash and cash equivalents was -CNY 28,556,812.86, compared to -CNY 6,749,165.61 last year[22]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,205,121,056.30, a decrease of 11.34% compared to the end of the previous year[3]. - The total assets of the company as of September 30, 2024, were RMB 1,205,121,056.30, down from RMB 1,359,312,015.51 at the end of 2023, a decrease of approximately 11.3%[13]. - The company's total liabilities decreased to ¥60,199,492.97 in Q3 2024 from ¥91,994,257.88 in Q3 2023, a reduction of 34.6%[15]. - The equity attributable to shareholders at the end of the reporting period was ¥1,140,866,373.20, down 9.82% from the previous year[3]. - The total equity attributable to shareholders decreased to ¥1,140,866,373.20 in Q3 2024 from ¥1,265,066,305.34 in Q3 2023, a decline of 9.8%[15]. Operational Efficiency - The company experienced a significant increase in cash flow from operating activities, indicating improved operational efficiency[3]. - The revenue growth in the reporting period was primarily driven by an increase in cash inflow from the sales of Cordyceps[9]. - The company reported a significant increase in payments to employees, totaling CNY 19,129,170.98, compared to CNY 17,571,263.51[21]. - Tax payments increased to CNY 16,625,130.74 from CNY 10,840,488.25 in the previous period[21]. Research and Development - Research and development expenses increased to ¥10,437,424.73 in 2024 from ¥7,554,555.90 in 2023, representing a growth of 38.5%[16]. - The company has not reported any new strategies or significant developments in product or technology research during the reporting period[10]. Shareholder Information - The top ten shareholders held a total of 41,252 shares, with the largest shareholder, Tibet Rong'en Technology Co., Ltd., owning 32.13% of the shares[9]. - The company has not disclosed any significant changes in the participation of major shareholders in margin trading or securities lending activities[10].